Targeting latency-associated peptide promotes antitumor immunity

Science Immunology

Volumn 2, Issue 11, 2017, Pages

  Gabriely, Galina ^a   Da Cunha, Andre P ^a,b   Rezende, Rafael M ^a   Kenyon, Brendan ^a   Madi, Asaf ^a   Vandeventer, Tyler ^a   Skillin, Nathaniel ^a   Rubino, Stephen ^a   Garo, Lucien ^a   Mazzola, Maria A ^a   Kolypetri, Panagiota ^a   Lanser, Amanda J ^a   Moreira, Thais ^c   Faria, Ana Maria C ^c   Lassmann, Hans ^d   Kuchroo, Vijay ^a   Murugaiyan, Gopal ^a   Weiner, Howard L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d Medical University of Vienna   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85021149074     PISSN: None     EISSN: 24709468     Source Type: Journal    
DOI: 10.1126/sciimmunol.aaj1738     Document Type: Article

References (53)

1. + regulatory T cells. Nat. Immunol. 4, 330–336 (2003).
2. S. Hori, T. Nomura, S. Sakaguchi, Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057–1061 (2003).
3. + T cells. Nat. Med. 12, 627–635 (2006).
4. M. G. Roncarolo, S. Gregori, M. Battaglia, R. Bacchetta, K. Fleischhauer, M. K. Levings, Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212, 28–50 (2006).
5. + regulatory T cell subset with TGF-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. J. Immunol. 180, 7327–7337 (2008).
6. A. P. da Cunha, H. Y. Wu, R. M. Rezende, T. Vandeventer, H. L. Weiner, In vivo anti-LAP mAb enhances IL-17/IFN- responses and abrogates anti-CD3-induced oral tolerance. Int. Immunol. 27, 73–82 (2015).
7. + regulatory T cells. Mucosal Immunol. 7, 428–439 (2014).
8. H.-B. Jie, N. Gildener-Leapman, J. Li, R. M. Srivastava, S. P. Gibson, T. L. Whiteside, R. L. Ferris, Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br. J. Cancer 109, 2629–2635 (2013).
9. D. A. Thomas, J. Massague, TGF- directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369–380 (2005).
10. M. A. Travis, D. Sheppard, TGF- activation and function in immunity. Annu. Rev. Immunol. 32, 51–82 (2014).
11. M. Pickup, S. Novitskiy, H. L. Moses, The roles of TGF in the tumour microenvironment. Nat. Rev. Cancer 13, 788–799 (2013).
12. R. Wang, J. Zhu, X. Dong, M. Shi, C. Lu, T. A. Springer, GARP regulates the bioavailability and activation of TGF. Mol. Biol. Cell 23, 1129–1139 (2012).
13. D. B. Rifkin, Latent transforming growth factor- (TGF-) binding proteins: Orchestrators of TGF- availability. J. Biol. Chem. 280, 7409–7412 (2005).
14. J. Stockis, D. Colau, P. G. Coulie, S. Lucas, Membrane protein GARP is a receptor for latent TGF- on the surface of activated human Treg. Eur. J. Immunol. 39, 3315–3322 (2009).
15. T. Oida, H. L. Weiner, TGF- induces surface LAP expression on murine CD4 T cells independent of Foxp3 induction. PLOS ONE 5, e15523 (2010).
16. Y. Zheng, A. Chaudhry, A. Kas, P. deRoos, J. M. Kim, T.-T. Chu, L. Corcoran, P. Treuting, U. Klein, A. Y. Rudensky, Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control TH2 responses. Nature 458, 351–356 (2009).
17. M. Zhang, H. Tang, Z. Guo, H. An, X. Zhu, W. Song, J. Guo, X. Huang, T. Chen, J. Wang, X. Cao, Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat. Immunol. 5, 1124–1133 (2004).
18. S. Song, P. Yuan, H. Wu, J. Chen, J. Fu, P. Li, J. Lu, W. Wei, Dendritic cells with an increased PD-L1 by TGF- induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells. Int. Immunopharmacol. 20, 117–123 (2014).
19. M. B. Mokrani, J. Klibi, D. Bluteau, G. Bismuth, F. Mami-Chouaib, Smad and NFAT pathways cooperate to induce CD103 expression in human CD8 T lymphocytes. J. Immunol. 192, 2471–2479 (2014).
20. + T cells promotes selective destruction of the host intestinal epithelium during graft-versus-host disease. J. Exp. Med. 201, 1647–1657 (2005).
21. + regulatory T cells. Science 349, 993–997 (2015).
22. + regulatory T cells in humans. Proc. Natl. Acad. Sci. U.S.A. 106, 4793–4798 (2009).
23. P. D. Bos, A. Y. Rudensky, Treg cells in cancer: A case of multiple personality disorder. Sci. Transl. Med. 4, 164fs44 (2012).
24. + T cell differentiation. J. Immunol. 187, 4967–4978 (2011).
25. + T cell priming regulate the generation of central memory cells. J. Immunol. 185, 263–272 (2010).
26. + T cell fates in the antitumor immune response. J. Immunol. Res. 2016, 8941260 (2016).
27. C. Liu, C. J. Workman, D. A. A. Vignali, Targeting regulatory T cells in tumors. FEBS J. 283, 2731–2748 (2016).
28. H. Pere, C. Tanchot, J. Bayry, M. Terme, J. Taieb, C. Badoual, O. Adotevi, N. Merillon, E. Marcheteau, V. R. Quillien, C. Banissi, A. Carpentier, F. Sandoval, M. Nizard, F. Quintin-Colonna, G. Kroemer, W. H. Fridman, L. Zitvogel, S. P. Oudard, E. Tartour, Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology 1, 326–333 (2012).
29. + T cells are suppressors accumulated in the tumor sites and associated with the progression of colorectal cancer. Clin. Cancer Res. 18, 5224–5233 (2012).
30. + T cells. Eur. J. Immunol. 37, 129–138 (2007).
31. + T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat. Med. 22, 679–684 (2016).
32. + CTL. J. Immunol. 159, 3748–3756 (1997).
33. K.-L. Ling, N. Dulphy, P. Bahl, M. Salio, K. Maskell, J. Piris, B. F. Warren, B. D. George, N. J. Mortensen, V. Cerundolo, Modulation of CD103 expression on human colon carcinoma-specific CTL. J. Immunol. 178, 2908–2915 (2007).
34. D. Anz, W. Mueller, M. Golic, W. G. Kunz, M. Rapp, V. H. Koelzer, J. Ellermeier, J. W. Ellwart, M. Schnurr, C. Bourquin, S. Endres, CD103 is a hallmark of tumor-infiltrating regulatory T cells. Int. J. Cancer 129, 2417–2426 (2011).
35. + T cells expressing the intraepithelial lymphocyte marker CD103 (E/7 integrin) in high-grade serous ovarian cancer. Gynecol. Oncol. 118, 228–236 (2010).
36. + tumor–infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J. Immunol. 194, 3475–3486 (2015).
37. + regulatory T cells. J. Mol. Cell Biol. 6, 81–92 (2014).
38. + T cells. J. Immunol. 177, 2775–2783 (2006).
39. + T regulatory cells use a novel genetic program that includes CD103 to suppress Th1 immunity in eye-derived tolerance. Invest. Ophthalmol. Vis. Sci. 47, 1533–1542 (2006).
40. + regulatory T cells in spontaneous tolerance of liver allografts. Int. Immunopharmacol. 9, 546–548 (2009).
41. M. Mattoscio, R. Nicholas, M. P. Sormani, O. Malik, J. S. Lee, A. D. Waldman, F. Dazzi, P. A. Muraro, Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis. Neurology 84, 1473–1482 (2015).
42. + regulatory T cells via a TGF-– and retinoic acid–dependent mechanism. J. Exp. Med. 204, 1757–1764 (2007).
43. O. Annacker, J. L. Coombes, V. Malmstrom, H. H. Uhlig, T. Bourne, B. Johansson-Lindbom, W. W. Agace, C. M. Parker, F. Powrie, Essential role for CD103 in the T cell–mediated regulation of experimental colitis. J. Exp. Med. 202, 1051–1061 (2005).
44. + dendritic cells: Master regulators of tolerance? Trends Immunol. 32, 412–419 (2011).
45. R. Gandhi, D. E. Anderson, H. L. Weiner, Cutting Edge: Immature human dendritic cells express latency-associated peptide and inhibit T cell activation in a TGFdependent manner. J. Immunol. 178, 4017–4021 (2007).
46. Y. Zhang, R. Morgan, C. Chen, Y. Cai, E. Clark, W. N. Khan, S.-U. Shin, H.-M. Cho, A. Al Bayati, A. Pimentel, J. D. Rosenblatt, Mammary-tumor-educated B cells acquire LAP/TGF- and PD-L1 expression and suppress anti-tumor immune responses. Int. Immunol. 28, 423–433 (2016).
47. R. M. Rezende, A. P. da Cunha, C. Kuhn, S. Rubino, H. M’Hamdi, G. Gabriely, T. Vandeventer, S. Liu, R. Cialic, N. Pinheiro-Rosa, R. P. Oliveira, J. T. Gaublomme, N. Obholzer, J. Kozubek, N. Pochet, A. M. C. Faria, H. L. Weiner, Identification and characterization of latency-associated peptide-expressing T cells. Nat. Commun. 6, 8726 (2015).
48. + Treg suppress EAE by TGF and IFNdependent mechanisms. Eur. J. Immunol. 39, 3423–3435 (2009).
49. E. Cerami, J. Gao, U. Dogrusoz, B. E. Gross, S. O. Sumer, B. A. Aksoy, A. Jacobsen, C. J. Byrne, M. L. Heuer, E. Larsson, Y. Antipin, B. Reva, A. P. Goldberg, C. Sander, N. Schultz, The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
50. J. Gao, B. A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S. O. Sumer, Y. Sun, A. Jacobsen, R. Sinha, E. Larsson, E. Cerami, C. Sander, N. Schultz, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
51. J. R. Ohlfest, B. M. Andersen, A. J. Litterman, J. Xia, C. A. Pennell, L. E. Swier, A. M. Salazar, M. R. Olin, Vaccine injection site matters: Qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model. J. Immunol. 190, 613–620 (2013).
52. S. S. Ahuja, In vitro generation of functional human and murine dendritic cells. Methods Mol. Biol. 156, 67–77 (2001).
53. G. K. Smyth, Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article3 (2004).